CP 301
Alternative Names: CP-301Latest Information Update: 22 Jan 2023
Price :
$50 *
At a glance
- Originator Contera Pharma; Vernalis
- Class Small interfering RNA
- Mechanism of Action Gene silencing; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Peripheral nervous system diseases
Most Recent Events
- 28 Nov 2022 Early research in Peripheral nervous system diseases in Denmark (unspecified route) (Contera Pharma pipeline, November 2022)
- 28 Nov 2022 Early research in Peripheral nervous system diseases in United Kingdom (unspecified route) (Contera Pharma pipeline, November 2022)
- 27 Sep 2022 Vernalis Research and Contera Pharma agree to co-promote and co-develop RNA targeting small molecules in Denmark and United kingdom for Neurological disorders